© 1996 by Oxford University Press
Journal of the National Cancer Institute, Vol. 88, No. 10, 661-667,
May 15, 1996
© 1996 Oxford University Press
Psychological Symptoms and Disease-Free and Overall Survival in Women With Stage II Breast Cancer
New York State Psychiatric Institute New York City
Cancer and Leukemia Group B Statistical Office, Duke University Medical Center Durham, NC
Harvard School of Public Health Boston, MA
Memorial Sloan-Kettering Cancer Center New York, NY
Rush-Presbyterian-St. Lukes Medical Center Chicago, IL
Mount Sinai School of Medicine New York
West Virginia Health Sciences Center Morgantown
University of California-San Diego Minneapolis
University of Minnesota Minneapolis
Division of Cancer Prevention and Control, National Cancer Institute Bethesda, MD
Emory University School of Medicine Atlanta, GA
Correspondence to: Susan Tross, Ph.D., New York State Psychiatric Institute, HIV Center for Clinical and Behavioral Studies, 722 W. 168th St., Suite 1020, New York, NY 10032.
BACKGROUND:: The possible link between psychological factors and length of cancer survival has generated a literature of contradictory findings. Associations usually have not been found when general psychological symptoms are assessed. Associations usually have been found for predictors related to expressive versus repressive emotional coping (e.g., depression, "fighting spirit," hostility, and type C personality); however, even these associations have been relatively small, when compared with those for medical factors. Yet few studies have adequately controlled for medical and treatment-related factors.
PURPOSE:: Within a Cancer and Leukemia Group B (CALGB) national clinical trial of four adjuvant therapy regimens for stage II breast cancer (CALGB 8082), this study prospectively examined the contribution of potential psychological predictors to length of disease-free and overall survival over a 15-year period.
METHODS:: Subjects were 280 women with stage II breast cancer, out of a total of 899, who were randomly assigned to receive CMFVP (cyclophosphamide-metho-trexate-fluorouracil-vincristine-prednisone) for two 6-week cycles or six 4-week cycles, then subsequently randomly assigned to receive or not to receive VATH (vinblastine-doxorubicin-thiotepa-fluoxymesterone). Subjects were recruited during the period between October 1980 and August 1984, inclusive, and followed until January 1996. Prior to chemotherapy, psychological symptoms were assessed using the Symptom Check List-90-Revised (SCL-90-R). SCL-90-R scores were trichotomized into categories representing high, medium, and low distress. Basic base-line sociodemographic data (including age, ethnicity, education, and marital status) and medical data (including lymph node status, estrogen receptor status, menopausal status, and performance status) were collected. Subjects with psychosocial data differed from those without psychosocial data solely in their higher percentage of classification in the mild limitation category of the Zubrod (Eastern Cooperative Oncology Group) performance status rating (subjects with psychosocial data: 14%; subjects without psychosocial data: 8%).
RESULTS:: In stepwise Cox regression analyses that controlled for sociodemographic and medical variables, there was no significant predictive effect of the level of distress (as measured by the SCL-90-R trichotomized scores) on length of disease-free and overall survival of the study subjects. Risk ratios for low versus high distress were 1.01 (95% confidence interval [CI] = 0.62–1.66) for disease-free survival and 1.03 (95% CI = 0.58–1.82) for overall survival.
CONCLUSIONS:: This study failed to provide evidence that psychological factors contributed to length of disease-free or overall survival of women who received adjuvant chemotherapy (either CMFVP alone or CMFVP followed by VATH) for treatment of stage II breast cancer.
IMPLICATIONS:: In the context of far more potent medical factors, the contribution of psychological factors to disease-free and overall survival is likely to be relatively small. Future research should focus on specific theory-driven predictors rather than on general psychological symptoms. Moreover, it should be based on clinical studies using a controlled, prospective design, in which the effects of medical factors may be distinguished and psychological predictors are clear antecedents of survival outcomes. [J Natl Cancer Inst 1996; 88: 661–7]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  F. Meyer, A. Fortin, M. Gelinas, A. Nabid, F. Brochet, B. Tetu, and I. Bairati Health-Related Quality of Life As a Survival Predictor for Patients With Localized Head and Neck Cancer Treated With Radiation Therapy J. Clin. Oncol., June 20, 2009; 27(18): 2970 - 2976. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. C. Gotay, C. T. Kawamoto, A. Bottomley, and F. Efficace The Prognostic Significance of Patient-Reported Outcomes in Cancer Clinical Trials J. Clin. Oncol., March 10, 2008; 26(8): 1355 - 1363. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. L. Weihs, T. M. Enright, and S. J. Simmens Close Relationships and Emotional Processing Predict Decreased Mortality in Women with Breast Cancer: Preliminary Evidence Psychosom Med, January 1, 2008; 70(1): 117 - 124. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. R. Kerr, H. N. Andrews, K. S. Strange, J. T. Emerman, and J. Weinberg Temporal Factors Alter Effects of Social Housing Conditions on Responses to Chemotherapy and Hormone Levels in a Shionogi Mammary Tumor Model Psychosom Med, November 1, 2006; 68(6): 966 - 975. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Collette, G. van Andel, A. Bottomley, G. O.N. Oosterhof, W. Albrecht, T. M. de Reijke, and S. D. Fossa Is Baseline Quality of Life Useful for Predicting Survival With Hormone-Refractory Prostate Cancer? A Pooled Analysis of Three Studies of the European Organisation for Research and Treatment of Cancer Genitourinary Group J. Clin. Oncol., October 1, 2004; 22(19): 3877 - 3885. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Efficace, P. Therasse, M. J. Piccart, C. Coens, K. Van Steen, M. Welnicka-Jaskiewicz, T. Cufer, J. Dyczka, M. Lichinitser, L. Shepherd, et al. Health-Related Quality of Life Parameters As Prognostic Factors in a Nonmetastatic Breast Cancer Population: An International Multicenter Study J. Clin. Oncol., August 15, 2004; 22(16): 3381 - 3388. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. W. Brown, A. R. Levy, Z. Rosberger, and L. Edgar Psychological Distress and Cancer Survival: A Follow-Up 10 Years After Diagnosis Psychosom Med, July 1, 2003; 65(4): 636 - 643. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. R. Kerr, R. Hundal, W. A. Silva, J. T. Emerman, and J. Weinberg Effects of Social Housing Condition on Chemotherapeutic Efficacy in a Shionogi Carcinoma (SC115) Mouse Tumor Model: Influences of Temporal Factors, Tumor Size, and Tumor Growth Rate Psychosom Med, November 1, 2001; 63(6): 973 - 984. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. Coates, C. Hurny, H. F. Peterson, J. Bernhard, M. Castiglione-Gertsch, R. D. Gelber, and A. Goldhirsch Quality-of-Life Scores Predict Outcome in Metastatic but Not Early Breast Cancer J. Clin. Oncol., November 15, 2000; 18(22): 3768 - 3774. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Reynolds, S. Hurley, M. Torres, J. Jackson, P. Boyd, and V. W. Chen Use of Coping Strategies and Breast Cancer Survival: Results from the Black/White Cancer Survival Study Am. J. Epidemiol., November 15, 2000; 152(10): 940 - 949. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Faller, H. Bulzebruck, P. Drings, and H. Lang Coping, Distress, and Survival Among Patients With Lung Cancer Arch Gen Psychiatry, August 1, 1999; 56(8): 756 - 762. [Abstract] [Full Text] [PDF]
|
|